Carotid Implants to Treat Resistant Arterial Hypertension

Andò, Giuseppe; Mahendiran, Thabo; Ando, Victoria

doi:10.1016/j.jcin.2021.12.045

Search citation statements

Order By: Relevance

Paper Sections

Select...

Endovascular Baroreflex Amplification1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In parallel, two clinical trials (NCT03179800 and NCT02827032, respectively) CT are evaluating the function of MobiusHD in decreasing BP levels while maintaining an acceptable safety profile. More randomized sham-controlled trials are required to demonstrate the effectiveness and safety of this approach, in which all medical teams collaborate to ensure the success of the MobiusHD device [ 74 ].…”

Section: Endovascular Baroreflex Amplificationmentioning

confidence: 99%

Device's design and clinical perspectives for resistant hypertension therapy

Jami,

Oussama,

Mohammed

et al. 2024

International Journal of Cardiology Cardiovascular Risk and Pre

View full text Add to dashboard Cite

Section: Endovascular Baroreflex Amplificationmentioning

confidence: 99%

Device's design and clinical perspectives for resistant hypertension therapy

Jami,

Oussama,

Mohammed

et al. 2024

International Journal of Cardiology Cardiovascular Risk and Pre

View full text Add to dashboard Cite

Device-Based Therapy for Resistant Hypertension: An Up‐to‐Date Review

Jami

Tijani

Ettahir

2022

High Blood Press Cardiovasc Prev

View full text Add to dashboard Cite

Hypertension is the major risk factor for cardiovascular morbidity and mortality. Matter of fact, untreated hypertension can worsen the overall health, whereas pharmacotherapy can play an important role in lowering the risk of high blood pressure in hypertensive patients. However, persistent uncontrolled hypertension remains an unsolved condition characterized by non-adherence to medication and increased sympathetic activity. This paper will review the non-pharmacological treatments for resistant hypertension (RH) that have emerged in recent years. In addition, the technologies developed in device-based RH therapy, as well as the clinical trials that support their use, will be discussed. Indeed, the novel device-based approaches that target RH present a promising therapy which has been supported by several studies and clinical trials, whereas drug non-adherence and high sympathetic activity are known to be the main causes of RH. Nevertheless, some additional aspects of these RH systems need to be tested in the near future, with a particular focus on the device's design and availability of randomized controlled trials.

show abstract